Vion files Onrigin in US for acute myeloid leukaemia
This article was originally published in Scrip
Executive Summary
Vion Pharmaceuticals has filed an NDA with the US FDA for its lead oncology drug candidate Onrigin (laromustine; formerly Cloretazine (VNP40101M)) as a single agent for remission induction treatment for patients 60 years or older with de novo poor-risk acute myeloid leukaemia (AML).